a good month for deals

Looking back on the three partnerships to date it would appear that December is a good month for deals. Roche was signed in December 2009 and Astrazeneca in December 2010.

Treating the AGM presentation as a jigsaw puzzle where you try and fit all the bits of corporate information together, it would appear that the slide titled Leveraging Discovery Alliances to Build Value would make a perfect corner piece. The slide portrays a potential revenue graph of cumulative deal making through to 2012. Unless some accounting boffin simply used a slide rule without thinking, the graph reveals that cumulative revenues will grow to approximately $500m by the end of 2011. Cumulative revenues to date from the Pfizer-Astrazeneca deals (Roche is unavailable) are $234m ie we are looking for approximately $250m in December to make the graph work.

Kpool provided an excellent synopsis of the AGM in his post of 24 November. "One of the deals Phylogica hope to sign before the end of the year alone already counts for $250m". There is no guarantee any deal will be signed but undoubtedly negotiations are well advanced for another December signing.